Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is an open-label, randomized, prospective, multicenter phase III trial to evaluate the efficacy and safety of the combination therapy of cetuximab with either pembrolizumab or finotonlimab, alongside chemotherapy, as a first-line treatment, compared with pembrolizumab or finotonlimab with chemotherapy for R/M HNSCC.
Epistemonikos ID: e9b08d5a1ed5bf3a0888b95ca61f42a651278096
First added on: Apr 04, 2026